Research programme: microbiome-targeted therapeutics - Kaleido Biosciences

Drug Profile

Research programme: microbiome-targeted therapeutics - Kaleido Biosciences

Latest Information Update: 03 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Kaleido Biosciences
  • Class Anti-infectives; Antineoplastics; Polysaccharides
  • Mechanism of Action Metagenome modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer; Inborn genetic disorders; Infections; Metabolic disorders

Most Recent Events

  • 25 Sep 2017 Kaleido Biosciences has patents pending for microbiome-targeted therapeutics globally and in Europe, Australia, USA
  • 18 Sep 2017 Kaleido Biosciences plans four clinical trials in 2017
  • 01 Dec 2015 Preclinical trials in Cancer in USA (unspecified route) before December 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top